Featured Research

from universities, journals, and other organizations

Use of non-psychoactive cannabinoids in the treatment of neurodegenerative diseases

Date:
September 19, 2008
Source:
Complutense University of Madrid
Summary:
Scientists have studied the effects of a drug that reduces the progression of a disease similar to multiple sclerosis in animals. This discovery represents another step in the standing fight against the disease.

The CB2 cannabinoids receptor is expressed in the cells that will form microglia, the main immune defence of the central nervous system.
Credit: Photograph: UCM

Scientists at the Complutense University of Madrid (UCM) have studied the effects of a drug that reduces the progression of a disease similar to multiple sclerosis in animals. This discovery represents another step in the standing fight against the disease.

The research, published in the Journal of Biological Chemistry, aimed to study in depth the already known effects of lessening the symptoms and stopping the advance of multiple sclerosis that cannabinoids have, while developing a drug that would not have the psychoactive effects of the marijuana plant (Cannabis sativa). To achieve this, the scientists have focused their study on the role of the cannabinoids receptor CB2, present both in the immune system as well as in the defence-cells of the nervous system (microglial cells).

Multiple sclerosis is a neurodegenerative disease whose causes are not yet fully understood. It is known that the disease is produced by an autoimmune response where the defence-cells in the organism attack and destroy the nerve cells of the organism generating symptoms such as stiffness, twitching, progressive paralysis, etc.

The researchers managed by Professor Ismael Galve from the UCM, founded their conclusions on the role of the cannabinoids receptors in Experimental autoimmune encephalomyelitis, a disease that reproduces some of the processes and symptoms of multiple sclerosis. In the study it has been tested that administering a drug that activates receptor CB2 (but not CB1, responsible for the psychactive effects), the symptoms of the disease lessen and a reduction of 50% in nerve cell loss was perceived.

This research has introduced yet another novelty: The stimulation of the CB2 receptor not only reduces the excessive activation of brain cells in charge of the defence of the central nervous system, but it also reduces the supply of new defence-cells that travelling throughout the blood stream from bone marrow, would act as reinforcements for the defence-cells of the central nervous system.

According to Ismael Galve, the results are important because the drug is capable of acting in an already sick animal, reducing the symptoms and the brain cell loss. The obtained results, along with other predecessors confirm the role of endogenous cannabinoids in the origin of experimental autoimmune encephalomyelitis and its possible application to multiple sclerosis. Therefore the role of the CB2 receptor in the regulation and neuro-immune response supports the research currently being carried out on the possible use of cannabinoid drugs in the treatment of neurodegenerative diseases.

The research has been carried out by the department of biochemistry and molecular biology of the Complutense University of Madrid, in collaboration with the Neuroscience research Institute of Lyon in France and the pharmaceutical company Pharmos.


Story Source:

The above story is based on materials provided by Complutense University of Madrid. Note: Materials may be edited for content and length.


Journal Reference:

  1. J. Palazuelos, N. Davoust, B. Julien, E. Hatterer, T. Aguado, R. Mechoulam, C. Benito, J. Romero, A. Silva, M. Guzman, S. Nataf, I. Galve-Roperh. The CB2 Cannabinoid Receptor Controls Myeloid Progenitor Trafficking: Involvement In The Pathogenesis Of An Animal Model Of Multiple Sclerosis. Journal of Biological Chemistry, 2008; 283 (19): 13320 DOI: 10.1074/jbc.M707960200

Cite This Page:

Complutense University of Madrid. "Use of non-psychoactive cannabinoids in the treatment of neurodegenerative diseases." ScienceDaily. ScienceDaily, 19 September 2008. <www.sciencedaily.com/releases/2008/09/080916154721.htm>.
Complutense University of Madrid. (2008, September 19). Use of non-psychoactive cannabinoids in the treatment of neurodegenerative diseases. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2008/09/080916154721.htm
Complutense University of Madrid. "Use of non-psychoactive cannabinoids in the treatment of neurodegenerative diseases." ScienceDaily. www.sciencedaily.com/releases/2008/09/080916154721.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins